Orthocell see 89% of patients return to work pain-free
04 Sep 2019 - Regenerative medicine company Orthocell (ASX:OCC) reports the final results from patients who completed the CelGro® tendon regeneration clinical trial showing 89 per cent of patients return to work and recreation pain-free.